Epigenetics: Drugs and Diagnostic Technologies

What is Epigenetics?

Epigenetics is a study of change in gene expression in a phenotype without changing the genotype. Epigenetics drugs and diagnostics are used while screening early stage cancer and other abnormal changes in skin cells, liver cells, brain cells and others.

Access Full PDF >>

Epigenetics Drugs and Diagnostic Technologies segmentation:

Epigenetics Drugs and Diagnostic Technologies Product

• Reagents, Kits, Instruments, Enzymes, Services

Epigenetics Drugs and Diagnostic Technologies Technology

• DNA Methylation, Histone Methylation, Histone Acetylation, Large Non-coding RNA, MicroRNA Modification, Chromatin Structures

Epigenetics Drugs and Diagnostic Technologies Type

• Histone Deacetylase (HDAC) Inhibitors, DNA Methyltransferase (DNMT) Inhibitors,

Epigenetics Drugs and Diagnostic Technologies Application

• Oncology, Non-oncology

Targeting Epigenetic Mechanisms: Considerations & Challenges

Due to the limited number of enzymes involved in DNA methylation, there has been hesitancy to consider them as suitable therapeutic targets – as inhibiting these enzymes would likely lead to broad and potentially serious adverse toxicological effects. Firestein cautions: “If we focused more on remodeling the chromatin by targeting enzymes that are responsible for creating the epigenetic marks, one concern could be potential side effects. These inhibitors could have an effect on disease-related genes as well as genes involved with normal cell function. The balance between safety and efficacy could be a very fine line.”

An alternative option may be to target the process and regulation of histone modification – as it requires a vast number of proteins with specialized roles – this individual functionality aids one’s ability to selectively target a specific protein, thereby limiting chances of toxicity.

However, identifying the right target may not be easy, explains Firestein: “One of the key challenges is wading through the multitude of potential targets and prioritizing them. There is no shortage of abnormally regulated genes, and it would be very difficult to test them all.”

“However, a primary advantage is the unbiased nature of the research and the ability to find the unexpected…”

Epigenetics Drugs and Diagnostic Technologies Industry Players are

Roche Diagnostics, Thermo Fisher Scientific, Eisai Co., Novartis AG, Illumina, QIAGEN, Abcam PLC, Merck KGaA., Genome Profiling, HistoGeneX N.V and others

I hope this article was helpful regarding? and I am sure you’ll have more questions.

Submit Your Question @ Here

Reference

• theinsightpartners.com
• technologynetworks.com